Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Medical University of Vienna, Department of Nephrology and Dialysis, Vienna, Austria
FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina, United States
Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
Neuromuskuläres Zentrum, Universitätsspital Basel, Basel, Switzerland
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital, Le KREMLIN-BICETRE, France
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.